For the full-year 2023, the Company anticipates double-digit Galafold revenue growth of 12-17% at constant exchange rates, CER. Growth is expected to be driven by continued underlying demand from both switch and treatment-naive patients, geographic expansion, continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Amicus receives positive CHMP opinion for Pombiliti for LOPD
- Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
- Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference